Subjects ages 18 years and older with beta thalassemia requiring chronic transfusions with associated iron overload requiring chelation therapy are eligible to participate.
The study involves administration of an experimental oral chelator once daily for either 14 or 28 days. Physical exams, neurologic exams, blood and urine tests, ECGs, and interviews will be performed to monitor for safety.